Ahmed A El-Sherif
Overview
Explore the profile of Ahmed A El-Sherif including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saada A, Gaith M, El-Sherif A, El-Deab M
Sci Rep
. 2025 Jan;
15(1):2429.
PMID: 39827267
This paper addresses the enhancement of formic acid electrooxidation (FAO) at Pt and Pt-NiOx nanoparticles based-catalysts assisted with urea derivatives as blending fuels. Blending formic acid with various ratios of...
2.
Mohamed H, Hemdan S, El-Sherif A
Sci Rep
. 2025 Jan;
15(1):1543.
PMID: 39789066
Yttrium oxide nanoparticles (YONPs) have emerged as a promising avenue for cancer therapy, primarily due to their distinctive properties that facilitate selective targeting of cancer cells. Despite their potential, the...
3.
Mansour M, Abdelkarim A, El-Sherif A, Mahmoud W
BMC Chem
. 2024 Aug;
18(1):150.
PMID: 39127681
Mixed ligand complexes of manganese(II), cobalt(II), copper(II), and cadmium(II)with an innovative Schiff base ligand denoted as (L), 4-(2-((1E,2E)-1-(2-(p-tolyl)hydrazineylidene)propan-2-ylidene)hydrazineyl), served as the principal ligand, while glycine (L2) was employed as secondary...
4.
Mosleh A, El-Sherif A, El-Sayed A, Fahmy H
Cell Biochem Biophys
. 2024 May;
82(2):1225-1234.
PMID: 38744782
The treatment of cancer often leads to a range of adverse effects. Encapsulating drugs can mitigate these effects and enhance drug efficacy by enabling a controlled release at the site...
5.
Fahmy H, Abdel-Rahman F, El-Sayed A, El-Sherif A
BMC Chem
. 2023 Jul;
17(1):78.
PMID: 37454081
Metallic antitumor drugs with heterocyclic ligands, such as novel AMI (amino methyl imidazole) complexes [Pd(AMI)Cl](1), [Cu(AMI)L](2), and [Cu(AMI)L·2HO](3) where L = oxalate and L = malonate, were synthesized and characterized....
6.
Elzayat E, Shahien S, El-Sherif A, Hosney M
Sci Rep
. 2023 Jun;
13(1):9613.
PMID: 37311848
Alzheimer's disease (AD) is one of the most common causes of dementia. Several drugs are used to improve the symptoms, but do not stop AD progression. There are more promising...
7.
Fahmy H, Mosleh A, El-Sayed A, El-Sherif A
J Trace Elem Med Biol
. 2023 Jun;
79:127236.
PMID: 37285632
Background: Schiff base metal complexes are considered promising chemotherapeutic agents due to their potential application in cancer therapy. Methods: The current work sought to synthesize a brand-new Schiff base ligand...
8.
Elzayat E, Shahien S, El-Sherif A, Hosney M
J Alzheimers Dis
. 2023 May;
94(s1):S203-S225.
PMID: 37212107
Alzheimer's disease (AD) is a cumulative progressive neurodegenerative disease characterized mainly by impairment in cognitive functions accompanied by memory loss, disturbance in behavior and personality, and difficulties in learning. Although...
9.
Sayed M, El-Sherif R, Ismail A, Abou Warda A, Mohamed A, El-Sherif A
Egypt Heart J
. 2023 Feb;
75(1):12.
PMID: 36780088
Background: Low-level laser therapy (LLLT) is a promising noninvasive physiotherapeutic approach that has been demonstrated to improve cardiac performance. This study aimed to assess the impact of low-level laser therapy...
10.
Mohamed H, Kamel G, El-Husseiny N, El-Sharkawy A, El-Sherif A, El-Shinawi M, et al.
Biochim Biophys Acta Mol Cell Res
. 2022 Oct;
1870(1):119367.
PMID: 36202317
Studies suggested that the pathogenesis of inflammatory breast cancer (IBC) is related to inflammatory manifestations accompanied by specific cellular and molecular mechanisms in the IBC tumor microenvironment (TME). IBC is...